Oryzon Bolsters Vafidemstat Patent Protection in Japan

Event summary

  • Oryzon Genomics received a ‘Decision to grant’ from the Japanese Patent Office for patent application JP2023-136283 covering vafidemstat’s use in treating aggression and social withdrawal.
  • The granted patent, expected to remain in force until at least 2038 (excluding potential extensions), covers treatment of aggression and social withdrawal.
  • Oryzon already holds corresponding patents or allowances in Europe, Australia, Canada, Hong Kong, Israel, South Korea, Malaysia, the Philippines, and Russia.
  • The company is preparing Phase III trials for BPD aggression and Phase II trials for ASD and schizophrenia, utilizing vafidemstat.

The big picture

This patent grant strengthens Oryzon’s IP position for vafidemstat, a key asset in the company’s pipeline targeting CNS disorders. The company’s focus on epigenetics and personalized medicine represents a growing trend in biopharmaceutical development, but faces challenges in demonstrating clinical efficacy and navigating complex regulatory pathways. Securing patent protection in key markets like Japan is essential for maximizing the commercial value of vafidemstat and supporting Oryzon’s long-term growth strategy.

What we're watching

Clinical Execution
The success of Oryzon’s upcoming Phase III trial in BPD will be critical to validating vafidemstat’s efficacy and commercial potential, given the relatively high unmet need in this patient population.
Regulatory Landscape
The speed of regulatory approval in Japan, a key market, will influence Oryzon’s overall commercialization timeline and revenue projections for vafidemstat.
Patent Defense
Oryzon will need to actively defend its patent portfolio against potential challenges, as competitors may seek to develop similar LSD1 inhibitors for CNS disorders.